A new venture fund engaged Alacrita to identify assets available for in-licensing to anchor a new startup in autoimmune or immunology indications. Modalities included small molecules, gene therapies, and biologics at IND-ready through Phase 3 stages.

Over 3 months, 95 assets were identified meeting the client's criteria and discussions with 15 asset owners were initiated. We provided a final asset scouting database with conclusions and recommended next steps.

A biotech with a focus on fibroblast biology wanted to expand its pipeline by in-licensing preclinical-stage assets modulating pathogenic fibroblasts. After conducting scouting in-house, the company engaged Alacrita for additional support.

Our search used internal databases, subscription intelligence databases, Alacrita's expert network, grant databases, research charities, and conference sources. Through periodic meetings to review emerging opportunities and refine criteria, we finalized a long list of early-stage opportunities in the fibroblast space. Approximately 25 new assets identified by Alacrita had not been previously found by the client.

A Phase 2 clinical-stage company sought to supplement its pipeline with immune-oncology or vaccine assets from financially distressed companies. Modalities of interest included nucleic acids, oncolytic viruses, cell therapies, peptides, protein degraders, enzymes, and platform technologies.

From an initial pool of 5,500 potential assets, we identified those owned by vulnerable companies, detailed them in a prioritized database, and conducted targeted outreach. We contacted 51 distressed companies regarding 99 assets of interest, evaluated non-confidential data packages, and the client was ultimately introduced to 3 companies for further partnering discussions.

A rapidly growing European specialty medtech company wanted acquisition targets in interventional medicine that would complement its existing infrastructure and organic growth strategy. Disease areas included interventional radiology, oncology, vascular disease, cardiology, pulmonary, GI, and urinary.

With our medtech consultant network, we identified over 1,500 potential targets ranging from research-stage SMEs to listed companies. Over two weeks, we refined this to approximately 120 companies, then shortlisted 20 for in-depth profiling, recommending a final selection of 5 preferred targets. One opportunity stood out as a potential transformative merger.

A disease area unit within a global biopharma company needed to identify novel candidate assets for IBD and celiac disease across modalities (with particular interest in microbiome and tolerance induction), primarily at candidate stage within 18 months of IND.

Initial pipeline database search was supplemented by secondary searches of TTO and SBIR grant databases, biotech incubators, and VC portfolio companies. Over a three-month campaign, more than 2,000 asset opportunities were evaluated and the client received over 100 assets approved for outreach, producing several attractive opportunities for partnering discussions.

An early-stage biotech with technology capable of eliminating NAb-producing B-cells wanted to identify discontinued antibody, protein, or peptide assets where NAbs (not safety or efficacy) were the reason for discontinuation.

We designed a search strategy recognizing that NAb information rarely appears in commercial pipeline databases. From more than 1,000 qualifying programs, 42 were discovered meeting the client's specific criteria and 174 additional assets were flagged for further investigation. Findings were cataloged in a shared database on a rolling basis.

A commercial-stage biotech focused on rare and ultra-rare diseases had established BD in North America but limited capacity in Europe. Alacrita was engaged to identify promising drug candidates, technologies, and research capabilities with transformational potential in selected rare diseases.

Using secondary research across scientific and patent literature, clinical trial databases, and translational medicine networks, combined with our clinical contact networks, we identified a long list of prospective technologies and product candidates. Each was screened for transformational potential through literature review, mechanism analysis, and discussions with originating scientists, producing a prioritized list of viable in-licensing opportunities.

A publicly-traded precision oncology company with whom Alacrita had a long-term scouting relationship wanted to explore pipeline expansion through acquisition of financially distressed biotech companies with complementary programs.

We built a database of companies developing oncology drugs with complementary mechanisms of action, profiled financial fitness to identify targets with short runways or depleted cash, and assessed each qualifying company's assets for portfolio fit. After consideration of several hundred companies, the client decided not to proceed with an acquisition at that time but was confident the search had been exhaustive.